Table 1. Datasets included.
| Site | IPD Analysis | Meningitis Analysis | ||||||
| <5 y | 18–49 y | 50–64 y | ≥65 y | <5 y | 18–49 y | 50–64 y | ≥65 y | |
| Active Bacterial Core Surveillance (USA) | INCL | INCL | INCL | INCL | INCL | INCL | INCL | INCL |
| Alaska (USA) | INCL | INCL | INCL | INCL | INCL | INCL | INCL | EXCLa |
| Australia Indigenous (Northern Territories) | INCL | INCL | INCL | INCL | INCL | No VT cases | INCL | No cases |
| Australia Non-Indigenous | INCL | INCL | INCL | INCL | INCL | EXCLa | INCL | INCL |
| Calgary (Canada) | INCL | INCL | INCL | INCL | INCL | INCL | INCL | INCL |
| Switzerland | INCL | INCL | INCL | INCL | INCL | INCL | INCL | INCL |
| Czech Republic | INCL | INCL | INCL | INCL | Data not provided | |||
| Denmark | INCL | INCL | INCL | INCL | INCL | INCL | INCL | INCL |
| England and Wales | INCL | INCL | INCL | INCL | INCL | INCL | INCL | INCL |
| France | EXCLa | Data not provided | INCL | Data not provided | ||||
| Greece (Crete) | INCL | INCL | INCL | INCL | INCL | No NVT cases | INCL | No VT cases |
| Ireland | EXCLa | INCL | EXCLa | EXCLa | INCL | |||
| Israel | INCL | Data did not include all cases | INCL | Data did not include all cases | ||||
| Navajo (USA) | INCL | INCL | INCL | INCL | INCL | INCL | No VT cases | No VT cases |
| Kaiser Permanente Northern California (USA) | INCL | Data not provided | INCL | Data not provided | ||||
| The Netherlands | INCL | INCL | INCL | INCL | INCL | INCL | INCL | INCL |
| Norway | INCL | INCL | INCL | INCL | EXCLa | INCL | INCL | EXCLa |
| New Zealand | INCL | INCL | INCL | INCL | INCL | INCL | INCL | INCL |
| Scotland | INCL | INCL | INCL | INCL | INCL | INCL | INCL | INCL |
| Uruguay | INCL | EXCLb | INCL | EXCLb | ||||
| Utah (USA) | INCLc | Data not provided | INCL | Data not provided | ||||
a
<50% serotyped in some years.
b
Major changes or biases in surveillance that could affect estimates of serotype-specific rate and could not be adjusted for in the analysis.
c
Included only in year +1; <50% serotyped in year 2.